For Arcus Orthotics, the name of the game is convenience. Staffed by a team of medical professionals, Arcus is an online custom orthotics company that creates custom insoles for shoppers from the ...

Shares of Arcus Biosciences, Inc. (RCUS) have gained 1.2% over the past four weeks to close the last trading session at $21.96, but there could still be a solid upside left in the stock if short-term ...

Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies HAYWARD, Calif., January 21, ...

Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for clear cell renal cell carcinoma (ccRCC) This is the second ...

Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical Oncology (ASCO); Fc-silent anti-TIGIT monoclonal antibody domvanalimab continued to ...

Gilead Sciences and Arcus are slimming down a phase 3 TIGIT trial to compare the lung cancer combo therapy to just Merck’s Keytruda, ditching a chemotherapy arm. The move means a little extra cash ...

Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board ...

Terry Rosen led Flexus Biosciences to a $1.25 billion acquisition by Bristol-Myers Squibb ($BMY) in roughly a year and a half. But now he and his team, including co ...

Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late ...

Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical ...